Cargando…

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study

BACKGROUND: Chronic lymphocytic leukemia (CLL) and other non-Hodgkin’s lymphomas (NHLs) lead to broad immunosuppression, conferring a greater risk for morbidity and mortality from SARS-CoV-2. Our study analyzed antibody (Ab) seropositivity from SARS-CoV-2 vaccination in patients with these cancers....

Descripción completa

Detalles Bibliográficos
Autores principales:	Doukas, Peter G, St. Pierre, Frederique, Karmali, Reem, Mi, Xinlei, Boyer, Jennifer, Nieves, Mariana, Ison, Michael G, Winter, Jane N, Gordon, Leo I, Ma, Shuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Hematologic Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546828/ https://www.ncbi.nlm.nih.gov/pubmed/37141401 http://dx.doi.org/10.1093/oncolo/oyad121

Ejemplares similares

Poster: CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
por: Karmali, Reem, et al.
Publicado: (2022)

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
por: Danilov, Alexey V, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B‐Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment
por: Liu, Hui, et al.
Publicado: (2018)

Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram
por: Liu, Junqi, et al.
Publicado: (2023)

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study
por: Musimar, Zola, et al.
Publicado: (2023)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials
por: Reinartz, Gabriele, et al.
Publicado: (2020)

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
por: Kaplan, Henry G, et al.
Publicado: (2022)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies
por: Samuelson, Clare, et al.
Publicado: (2016)

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation
por: Kubeczko, Marcin, et al.
Publicado: (2016)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)

More Insights on the Use of γ‐Secretase Inhibitors in Cancer Treatment
por: López‐Nieva, Pilar, et al.
Publicado: (2020)

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
por: Goyal, Gaurav, et al.
Publicado: (2022)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life
por: Jensen, Christopher E, et al.
Publicado: (2022)

A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
por: Zhao, Janice, et al.
Publicado: (2022)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Various inclusions in chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Galiacho, Verónica Roldán, et al.
Publicado: (2022)

Preoperative lymphocyte count, neutrophil to lymphocyte and platelet to lymphocyte ratio predict the recurrence with progression and cancerization in vocal fold lesions—retrospective study
por: Rzepakowska, Anna, et al.
Publicado: (2023)

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

How to diagnose lymphoplasmacytic lymphoma without infiltration of plasmacytoid lymphocytes?
por: Kassir, Ali El, et al.
Publicado: (2021)

Large cell lymphoma as initial presentation of undetected chronic lymphocytic leukemia
por: Park, Joowon
Publicado: (2012)

A simplified prognostic score for T-cell large granular lymphocyte leukaemia
por: Liu, Hailing, et al.
Publicado: (2023)

Clonal villous lymphocytes and plasma cells in splenic marginal zone lymphoma with plasmacytic differentiation
por: Souto Filho, João Tadeu Damian, et al.
Publicado: (2018)

The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma
por: Gong, Yi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jqimmrinndrplt32d9p01vrtug